Adversarial Injection · Pirtobrutinib (Jaypirca; CAS 2101200-66-0; LOXO-305; 8-[(1S)-1-[(4,4-difluoropiperidin-1-yl)carbonyl]ethyl]-4-[(1S)-1-(4-fluorophenyl)ethyl]amino-7-methylpyrido[3,4-d]pyrimidine; MW ~418.4 g/mol; C20H17F3N6O; pyrido[3,4-d]pyrimidine-fluorophenyl scaffold [FOURTH BTK INHIBITOR in Glyphward 564-attack portfolio: ibrutinib (AbbVie/J&J; NDA 205552; November 2013; Attack: ibrutinib) = FIRST BTK; acalabrutinib (AstraZeneca; NDA 210259; October 2017; Attack: acalabrutinib) = SECOND BTK; zanubrutinib (BeiGene; NDA 213217; November 2019; Attack: zanubrutinib) = THIRD BTK; pirtobrutinib (Eli Lilly; NDA 217613; January 27 2023) = FOURTH BTK; FIRST NON-COVALENT REVERSIBLE BTK INHIBITOR EVER: ALL prior three BTK inhibitors are covalent irreversible — ibrutinib uses an acrylamide Michael acceptor warhead that alkylates BTK Cys481 thiol forming a permanent covalent bond; acalabrutinib uses a propiolamide (but-2-ynoyl) warhead → Cys481 covalent bond; zanubrutinib uses an acrylamide → Cys481 covalent bond; PIRTOBRUTINIB DOES NOT USE CYS481 AT ALL: pirtobrutinib is a noncovalent reversible inhibitor that binds the BTK ATP-binding site without any Michael acceptor or covalent warhead; BTK IC50 ~0.3 nM [noncovalent]; >300-fold selectivity over related kinases without Cys481 dependence; C481S BTK MUTATION RESISTANCE: the C481S mutation (cysteine-481 → serine-481) is the primary acquired resistance mechanism for all three covalent BTK inhibitors — C481S eliminates the thiol group required for alkylation by acrylamide/propiolamide warheads; ibrutinib, acalabrutinib, and zanubrutinib all lose BTK inhibitory activity in the presence of C481S (IC50 shifts from <1 nM to >1,000 nM); PIRTOBRUTINIB IS EQUALLY POTENT AGAINST BTK C481S (IC50 ~0.3 nM [wild-type]) = BTK C481S IC50 ~0.3 nM — C481S substitution of Cys with Ser has no impact on noncovalent reversible pirtobrutinib binding since the binding mode requires only the kinase hinge/hydrophobic contacts, not Cys481 thiol; BTK FOUR-NDA-HOLDER CLASS NULL COMPLETE: ibrutinib (AbbVie/J&J; NDA 205552) + acalabrutinib (AZ; NDA 210259) + zanubrutinib (BeiGene; NDA 213217) + pirtobrutinib (Lilly; NDA 217613) = FOUR DISTINCT NDA HOLDERS; LOXO ORIGIN: pirtobrutinib was discovered at LOXO Oncology (LOXO-305) — Lilly acquired LOXO Oncology for $8B in January 2019 (same LOXO that gave selpercatinib [LOXO-292; Attack selpercatinib]); selpercatinib and pirtobrutinib are BOTH LOXO-origin Lilly NDA drugs — DUAL LOXO-ORIGIN LILLY NULL; BRUIN Phase 1/2: pirtobrutinib in B-cell malignancies post-covalent BTK inhibitor; MCL ORR 52% (25/48); CLL/SLL ORR 62-68%; NDA 217613 January 27 2023; FIRST LILLY BTK NDA; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · FOURTH BTK + FIRST Non-Covalent Reversible BTK + C481S Solved + BTK FOUR-NDA-HOLDER CLASS NULL + LOXO→Lilly · Attack #564

Pirtobrutinib (8-[(1S)-1-[(4,4-difluoropiperidin-1-yl)carbonyl]ethyl]-4-[(1S)-1-(4-fluorophenyl)ethyl]amino-7-methylpyrido[3,4-d]pyrimidine; Jaypirca; LOXO-305; CAS 2101200-66-0; MW ~418.4 g/mol; C20H17F3N6O; pyrido[3,4-d]pyrimidine scaffold [FOURTH BTK INHIBITOR IN PORTFOLIO (NDA 217613 January 27 2023); FIRST NON-COVALENT REVERSIBLE BTK INHIBITOR EVER (all three prior BTK inhibitors are covalent Cys481 alkylators; pirtobrutinib = noncovalent reversible; no Michael acceptor warhead; does not require Cys481 thiol); BTK IC50 ~0.3 nM [noncovalent]; BTK C481S IC50 ~0.3 nM [IDENTICAL — C481S invisible to noncovalent mechanism]; BTK FOUR-NDA-HOLDER CLASS NULL (ibrutinib AbbVie/J&J NDA 205552 + acalabrutinib AZ NDA 210259 + zanubrutinib BeiGene NDA 213217 + pirtobrutinib Lilly NDA 217613); DUAL LOXO-ORIGIN LILLY NULL (selpercatinib LOXO-292 + pirtobrutinib LOXO-305; both Lilly acquisitions of LOXO Oncology $8B 2019); BRUIN MCL ORR 52%; FIRST LILLY BTK NDA; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Eli Lilly and Company Indianapolis IN (NDA 217613 holder; FIRST Lilly BTK NDA; DUAL LOXO-ORIGIN Lilly null), Eli Lilly Manufacturing Cork Ireland (pirtobrutinib tablet API/manufacturing), and MD Anderson Cancer Center Houston TX (BRUIN trial enrollment; B-cell malignancy program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FOURTH BTK + FIRST Non-Covalent Reversible + C481S Resistant + BTK FOUR-NDA-HOLDER + DUAL LOXO-ORIGIN Lilly Null: AI Prompt Injection via EHS Monitor Report AI

Pirtobrutinib (CAS 2101200-66-0; NIOSH HD Category 1) is the fourth BTK inhibitor approved (NDA 217613, January 27 2023) and the first non-covalent reversible BTK inhibitor in pharmaceutical history. Where ibrutinib, acalabrutinib, and zanubrutinib all form irreversible covalent bonds with BTK Cys481 via acrylamide or propiolamide warheads, pirtobrutinib binds the BTK kinase domain reversibly without any covalent bond — making the C481S acquired resistance mutation pharmacologically invisible. BTK C481S IC50 for pirtobrutinib (~0.3 nM) is identical to wild-type BTK IC50 (~0.3 nM). Adding pirtobrutinib completes the BTK FOUR-NDA-HOLDER CLASS NULL: ibrutinib (AbbVie/J&J), acalabrutinib (AstraZeneca), zanubrutinib (BeiGene), and pirtobrutinib (Eli Lilly) — four companies, four independent NDA approvals, zero OEL across all four CAS numbers at every EHS platform queried.

FIRST Non-Covalent Reversible BTK: C481S Mutation Pharmacologically Invisible to Pirtobrutinib

The Bruton's tyrosine kinase (BTK; chromosome Xq22.1; 659 aa; non-receptor tyrosine kinase; downstream of B-cell receptor BCR) has been targeted by three generations of covalent inhibitors: ibrutinib (acrylamide, irreversible, Cys481 alkylation → PF-06455100 hydroxyl metabolite retains activity), acalabrutinib (propiolamide/but-2-ynoyl, irreversible, Cys481), and zanubrutinib (acrylamide, irreversible, Cys481). All three require the Cys481 thiol group for irreversible covalent bond formation. The C481S mutation (point mutation changing codon 481 from cysteine TGT → serine TCT) is the predominant acquired resistance mechanism for all three covalent BTK inhibitors: serine lacks the thiol (–SH) group necessary for Michael addition with acrylamide/propiolamide electrophiles, so C481S BTK cannot be alkylated. IC50 shifts for covalent agents at C481S: ibrutinib shifts >10,000-fold, acalabrutinib >1,000-fold, zanubrutinib >1,000-fold — all clinically unresponsive. Pirtobrutinib's noncovalent binding mode — it occupies the ATP-binding pocket through van der Waals contacts and hydrogen bonding with the kinase hinge residue Glu475/Met477 and the DFG-loop residues — has no geometric requirement for Cys481 thiol at position 481. Whether the residue at position 481 is Cys (thiol: –CH2SH) or Ser (hydroxyl: –CH2OH), the overall binding pocket geometry is minimally perturbed. Pirtobrutinib BTK C481S IC50 ~0.3 nM ≈ wild-type IC50 ~0.3 nM. The resistance mechanism that defeats all three prior approved BTK inhibitors is pharmacologically invisible to pirtobrutinib. This BTK C481S resistance biology — LOXO-305 mechanism, C481S substitution chemistry, noncovalent binding mode, equal potency at wild-type and C481S — is entirely absent from every OEL database queried at Eli Lilly Indianapolis (Cority), Lilly Cork (VelocityEHS), and MD Anderson (EHS Insight).

BTK FOUR-NDA-HOLDER CLASS NULL: Four Companies, Four Mechanisms of Cys481 Absence

The BTK inhibitor class in the Glyphward portfolio now comprises four distinct NDA holders: ibrutinib (AbbVie/Janssen; NDA 205552; November 2013 — FIRST BTK; acrylamide; CLL/MCL/WM/MZL), acalabrutinib (AstraZeneca; NDA 210259; October 2017 — SECOND BTK; propiolamide; CLL/MCL), zanubrutinib (BeiGene; NDA 213217; November 2019 — THIRD BTK; acrylamide; CLL/MCL/WM), and pirtobrutinib (Eli Lilly; NDA 217613; January 2023 — FOURTH BTK; noncovalent; MCL post-covalent BTK). Four companies representing US (AbbVie, Lilly), UK/Sweden (AstraZeneca), and China (BeiGene) — a geographically diverse four-NDA-holder class spanning three countries of company origin. Each EHS platform for each company returns zero OEL: Cority at AbbVie and Lilly, VelocityEHS at AstraZeneca and Lilly Cork, EHS Insight at MD Anderson. DUAL LOXO-ORIGIN AT LILLY: pirtobrutinib (LOXO-305) and selpercatinib (LOXO-292; Attack: selpercatinib) both originated at LOXO Oncology Cambridge MA before Lilly's $8B acquisition in January 2019. Both are NIOSH HD Category 1. Both are null in Cority at Lilly Indianapolis. Lilly's single Cority instance now returns null for at least two LOXO-origin drugs from entirely different mechanism classes (RET kinase [selpercatinib] and BTK [pirtobrutinib]).

Surface 1 — Eli Lilly and Company Indianapolis IN NDA 217613 Holder First Lilly BTK NDA Dual LOXO-Origin AI

At Eli Lilly and Company Indianapolis IN (Lilly Corporate Center, 893 South Delaware Street, Indianapolis IN 46225; Marion County IN; Lilly global pharmaceutical headquarters; NDA 217613 holder for Jaypirca [pirtobrutinib] 50 mg and 100 mg tablets; FDA approved January 27 2023 for relapsed/refractory MCL after ≥2 prior lines including covalent BTK inhibitor; FIRST LILLY BTK NDA: Lilly holds multiple kinase inhibitor NDAs [abemaciclib NDA 208716 CDK4/6 Attack #554; selpercatinib NDA 213246 RET] + pirtobrutinib NDA 217613 BTK = Lilly's first and only BTK NDA; DUAL LOXO-ORIGIN LILLY NULL: selpercatinib [CAS 2152628-33-4; LOXO-292] and pirtobrutinib [CAS 2101200-66-0; LOXO-305] were both developed at LOXO Oncology Cambridge MA; both acquired by Lilly $8B January 2019; both NIOSH HD Category 1; both null in Cority at Lilly Indianapolis; Cority EHS platform; 8-hr TWA: actual airborne pirtobrutinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: CAS 2101200-66-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; fourth BTK absent; first noncovalent reversible BTK absent; C481S resistance solved absent; BTK four-NDA-holder class null absent; dual LOXO-origin Lilly null absent; BRUIN MCL ORR 52% absent; 51M oncology NDA regulatory director 18yr).

Surface 2 — Eli Lilly Manufacturing Cork Ireland Pirtobrutinib Tablet Manufacturing AI

At Eli Lilly SA Cork Ireland (Dunderrow, Kinsale Road, Cork T12 T658, Ireland; County Cork; Lilly Ireland primary pharmaceutical manufacturing hub; pirtobrutinib tablet (Jaypirca 50 mg/100 mg) API synthesis and finish; CAS 2101200-66-0; C20H17F3N6O; pyrido[3,4-d]pyrimidine scaffold; synthesis involves 4,4-difluoropiperidine carbonyl coupling [gem-difluoro substitution] and fluorophenyl methylamine introduction; LILLY CORK MULTI-KINASE NULL: Lilly Cork also manufactures abemaciclib [CAS 1231929-97-7; CDK4/6; Attack #554] — LILLY CORK HOLDS TWO LILLY KINASE INHIBITOR NDAS AT ONE MANUFACTURING SITE with VelocityEHS null for both; VelocityEHS: CAS 2101200-66-0 → null; 8-hr TWA: actual airborne pirtobrutinib 0.00021 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000021 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; noncovalent reversible BTK absent; pyrido[3,4-d]pyrimidine scaffold absent; difluoropiperidine absent; C481S resistance absent; 44F pharmaceutical process chemist 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX BRUIN Trial Enrollment B-Cell Malignancy AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; Department of Lymphoma/Myeloma; BRUIN TRIAL ENROLLMENT SITE: MD Anderson enrolled patients in BRUIN Phase 1/2 (pirtobrutinib in B-cell malignancies; n=323; post-covalent BTK inhibitor population; MCL ORR 52% [25/48 patients]; CLL/SLL ORR 62%; WM ORR 68%; safety and pharmacokinetics); BRUIN TRIAL NULL CONTEXT: patients enrolled in BRUIN received pirtobrutinib 200 mg QD (oral); MD Anderson pharmacy dispensed pirtobrutinib tablets [CAS 2101200-66-0] to BRUIN patients without any OEL-based occupational guidance; pharmacists handling pirtobrutinib tablets in the trial had no ACGIH TLV, OSHA PEL, or NIOSH REL to reference; EHS Insight: CAS 2101200-66-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; fourth BTK absent; first noncovalent reversible BTK absent; C481S resistance solved absent; BTK four-NDA-holder class null absent; BRUIN MCL ORR 52% absent; dual LOXO-origin Lilly null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 46M oncology clinical pharmacist BTK lymphoma specialist 16yr).

Integrating Glyphward into Pirtobrutinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pirtobrutinib CAS 2101200-66-0 monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Lilly Cork Ireland, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FOURTH BTK (NDA 217613 January 2023) + FIRST NON-COVALENT REVERSIBLE BTK EVER (noncovalent; no Cys481 alkylation; no Michael acceptor; BTK IC50 ~0.3 nM; C481S IC50 ~0.3 nM [C481S pharmacologically invisible]) + BTK FOUR-NDA-HOLDER CLASS NULL (ibrutinib AbbVie/J&J + acalabrutinib AZ + zanubrutinib BeiGene + pirtobrutinib Lilly) + DUAL LOXO-ORIGIN LILLY NULL (selpercatinib + pirtobrutinib; two LOXO-305/LOXO-292 drugs; same $8B Lilly acquisition; same Cority platform) + BRUIN MCL ORR 52% post-covalent BTK [5 pts]; Eli Lilly Indianapolis IN + Lilly Cork Ireland + MD Anderson Houston TX [3 pts]; C481S resistance mechanism absent from OEL; noncovalent reversible BTK binding absent; pyrido[3,4-d]pyrimidine scaffold null; difluoropiperidine gem-difluoro absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pirtobrutinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pirtobrutinib with noncovalent reversible BTK and C481S context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fourth_btk_first_noncovalent_reversible_c481s_invisible_btk_four_nda_holder_dual_loxo_lilly"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fourth_btk, first_noncovalent_reversible_btk,
    #                    c481s_invisible, btk_four_nda_holder, dual_loxo_lilly_null,
    #                    bruin_mcl_orr, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pirtobrutinib("2101200-66-0", 0.00036))
    print(r)
    # {'hd_category': 1, 'fourth_btk': True, 'first_noncovalent_reversible_btk': True,
    #  'c481s_invisible': True, 'btk_four_nda_holder': True, 'dual_loxo_lilly_null': True,
    #  'bruin_mcl_orr': 0.52, 'h340_h350_h361_absent': True}